MIRXES-B(02629)与N Health 建立战略伙伴关系及HELICORapid、FITRapid居家监测试剂盒获得监管批准

Core Viewpoint - The strategic partnership between MIRXES-B and N Health aims to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and improving patient outcomes in the region [1][2]. Group 1: Strategic Partnership - The partnership is established to leverage MIRXES-B's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear™ for gastric cancer and LUNGClear™ for lung cancer [2]. - The collaboration will introduce cancer screening tests across nearly 60 hospitals within the N Health network, supporting broader access to early disease detection services in Thailand and Southeast Asia [2]. - N Health aims to enhance its role in providing end-to-end healthcare solutions and expand the accessibility of advanced cancer screening nationwide, integrating cancer risk assessments into preventive care [2]. Group 2: Market Potential - Thailand's health check-up market is projected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025, indicating strong demand for advanced and targeted screening solutions [1]. - The increasing awareness of preventive healthcare and rising chronic disease prevalence create an ideal environment for adopting innovative diagnostic technologies like MIRXES-B's miRNA tests [1]. Group 3: New Product Launch - The company plans to launch new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand starting January 9, 2026, following approvals from the Thai FDA [3]. - These home test kits are designed to complement the core miRNA cancer screening solutions and are the first of their kind in the Thai market, featuring an innovative single-device design that minimizes processing steps and reduces contamination risks [3][4]. - The distribution of these test kits will be through modern trade and pharmacy channels across Thailand, aligning with evolving consumer healthcare behaviors and increasing demand for preventive, self-diagnostic solutions [4].